Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited - Laporan Laba Rugi (TTM)

Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited
SG ˙ SGX
US$ 2.93 ↑0.07 (2.45%)
2025-09-04
BAHAGING PRESYO
Laporan Laba Rugi (TTM)

Laporan Laba Rugi Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited menunjukkan perubahan pendapatan dan pengeluaran selama periode waktu tertentu. Data Laporan Laba Rugi meliputi Penjualan dan Pendapatan, Laba Kotor, Penelitian dan Pengembangan (R&D), Beban Penjualan, Umum dan Administrasi (SG&A), Laba Operasi, Beban Pajak Penghasilan, Beban Bunga, Pendapatan Non-Operasi, Laba per Saham (EPS), dan Saham yang Beredar.

Semua angka adalah kelipatan 1,000,000 kecuali unit per saham.

2020
09-30
2020
12-31
2021
03-31
2021
06-30
2021
09-30
2021
12-31
2022
03-31
2022
06-30
2022
09-30
2022
12-31
2023
03-31
2023
06-30
2023
09-30
2023
12-31
2024
03-31
2024
06-30
2024
09-30
2024
12-31
2025
03-31
2025
06-30
Revenue 6,773 6,604 6,775 6,954 6,999 6,908 6,970 7,042 7,118 8,249 8,514 8,563 8,479 8,222 8,153 8,099 8,040 7,307 6,676 5,993
Change (%) -2.51 2.59 2.64 0.65 -1.30 0.90 1.03 1.09 15.89 3.21 0.57 -0.98 -3.03 -0.84 -0.67 -0.72 -9.12 -8.63 -10.24
% of Revenue 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00
Cost Of Sales 4,107 4,024 4,106 4,213 4,145 4,161 4,249 4,283 4,341 4,992 4,950 4,941 4,904 4,632 4,539 4,455 4,301 3,804 3,173 2,482
Change (%) -2.04 2.04 2.62 -1.61 0.38 2.11 0.81 1.36 14.99 -0.83 -0.18 -0.76 -5.54 -2.01 -1.86 -3.44 -11.57 -16.57 -21.77
% of Revenue 60.64 60.93 60.60 60.59 59.23 60.24 60.96 60.82 60.99 60.51 58.14 57.71 57.83 56.34 55.67 55.01 53.50 52.06 47.53 41.43
Gross Operating Profit 2,666 2,580 2,669 2,741 2,854 2,747 2,721 2,759 2,777 3,258 3,564 3,621 3,575 3,590 3,614 3,644 3,739 3,503 3,503 3,510
Change (%) -3.23 3.45 2.68 4.13 -3.75 -0.93 1.38 0.66 17.29 9.41 1.61 -1.27 0.41 0.67 0.83 2.60 -6.30 -0.00 0.20
% of Revenue 39.36 39.07 39.40 39.41 40.77 39.76 39.04 39.18 39.01 39.49 41.86 42.29 42.17 43.66 44.33 44.99 46.50 47.94 52.47 58.57
SG&A 1,934 1,821 1,843 1,839 1,911 1,935 1,929 1,932 1,910 2,356 2,490 2,551 2,562 2,527 2,533 2,575 2,651 2,503 2,469 2,438
Change (%) -5.80 1.19 -0.23 3.91 1.25 -0.31 0.18 -1.16 23.39 5.67 2.46 0.42 -1.36 0.23 1.66 2.94 -5.56 -1.38 -1.23
% of Revenue 28.55 27.58 27.21 26.44 27.30 28.01 27.67 27.44 26.83 28.56 29.24 29.79 30.21 30.74 31.07 31.80 32.97 34.26 36.98 40.69
R&D 128 149 158 169 168 161 151 150 159 153 158 150 147 185 185 179 197 162 163 177
Change (%) 16.20 5.96 6.84 -0.36 -4.31 -5.99 -0.91 5.88 -3.59 3.17 -5.07 -1.75 25.27 0.29 -3.19 9.86 -17.55 0.64 8.48
% of Revenue 1.90 2.26 2.33 2.43 2.40 2.33 2.17 2.13 2.23 1.86 1.86 1.75 1.74 2.25 2.27 2.21 2.45 2.22 2.45 2.96
OpEx 6,216 6,053 6,178 6,293 6,302 6,321 6,394 6,434 6,478 7,578 7,679 7,717 7,688 7,401 7,308 7,261 7,205 6,533 5,874 5,173
Change (%) -2.63 2.07 1.87 0.14 0.29 1.17 0.62 0.69 16.97 1.34 0.49 -0.38 -3.73 -1.26 -0.64 -0.77 -9.33 -10.08 -11.93
% of Revenue 91.77 91.66 91.19 90.51 90.05 91.50 91.74 91.37 91.01 91.86 90.19 90.13 90.67 90.01 89.63 89.66 89.61 89.41 87.98 86.33
Operating Income 557 551 597 660 696 587 576 608 640 671 835 846 791 821 845 837 835 774 803 819
Change (%) -1.12 8.27 10.67 5.48 -15.71 -1.92 5.60 5.26 4.89 24.40 1.25 -6.41 3.75 2.97 -0.95 -0.27 -7.31 3.69 2.10
% of Revenue 8.23 8.34 8.81 9.49 9.95 8.50 8.26 8.63 8.99 8.14 9.81 9.87 9.33 9.99 10.37 10.34 10.39 10.59 12.02 13.67
Interest Expense -0 -0 -0 -0 -3 -3 -3 -5 -4 -10 -18 -26 -34 -36 -35 -37 -38 -40 -36 -27
Change (%) -97.09 -0.00 -0.00 44,100.66 -0.23 -0.00 53.83 -15.17 167.92 78.46 40.18 33.39 4.63 -3.41 6.09 2.48 6.76 -10.39 -24.66
% of Revenue -0.00 -0.00 -0.00 -0.00 -0.04 -0.04 -0.04 -0.06 -0.05 -0.12 -0.22 -0.30 -0.40 -0.44 -0.42 -0.45 -0.47 -0.55 -0.54 -0.45
Net Income 657 662 705 801 846 769 756 775 837 862 1,063 1,116 991 987 973 922 932 2,229 2,216 3,499
Change (%) 0.67 6.51 13.63 5.70 -9.13 -1.73 2.59 7.89 3.01 23.34 4.94 -11.16 -0.44 -1.36 -5.27 1.13 139.10 -0.59 57.89
% of Revenue 9.70 10.02 10.40 11.52 12.09 11.13 10.84 11.01 11.75 10.45 12.48 13.03 11.69 12.00 11.94 11.38 11.60 30.51 33.20 58.39

Source: Capital IQ

Other Listings
DE:2TZ
Fintel data has been cited in the following publications:
Daily Mail Fox Business Business Insider Wall Street Journal The Washington Post Bloomberg Financial Times Globe and Mail
NASDAQ.com Reuters The Guardian Associated Press FactCheck.org Snopes Politifact
Federal Register The Intercept Forbes Fortune Magazine TheStreet Time Magazine Canadian Broadcasting Corporation International Business Times
Cambridge University Press Investopedia MarketWatch NY Daily News Entrepreneur Newsweek Barron's El Economista